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Abstract
The gene therapy field is currently limited by the lack of vehicles that permit efficient gene delivery to specific cell or tissue
subsets. Native viral vector tropisms offer a powerful platform for transgene delivery but remain nonspecific, requiring
elevated viral doses to achieve efficacy. In order to improve upon these strategies, our group has focused on genetically
engineering targeting domains into viral capsid proteins, particularly those based on adenovirus serotype 5 (Ad5). Our
primary strategy is based on deletion of the fiber knob domain, to eliminate broad tissue specificity through the human
coxsackie-and-adenovirus receptor (hCAR), with seamless incorporation of ligands to re-direct Ad tropism to cell types that
express the cognate receptors. Previously, our group and others have demonstrated successful implementation of this
strategy in order to specifically target Ad to a number of surface molecules expressed on immortalized cell lines. Here, we
utilized phage biopanning to identify a myeloid cell-binding peptide (MBP), with the sequence WTLDRGY, and
demonstrated that MBP can be successfully incorporated into a knob-deleted Ad5. The resulting virus, Ad.MBP, results in
specific binding to primary myeloid cell types, as well as significantly higher transduction of these target populations ex
vivo, compared to unmodified Ad5. These data are the first step in demonstrating Ad targeting to cell types associated with
inflammatory disease.
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Introduction
Viral vectors are currently the most efficient means of gene
transfer into a number of cell types. However, their use for gene-
based therapies is often limited by the lack of vectors that can
achieve specific and efficient gene transfer into target cells of
interest. This is typically due to either broad tissue expression of
viral receptors, which limit vector specificity, or a complete lack of
receptor expression on the target cells [1]. Thus, much effort has
gone into de-targeting viral vector tropism to ubiquitously-
expressed receptors and retargeting them towards receptors that
are unique to cell types associated with a particular pathology.
Adenovirus serotype 5 (Ad5)-based vectors are particularly
suited for these de-targeting/retargeting efforts, as they have a
well-characterized biology, and Ad capsid proteins are permissive
to the significant alterations required for tropism changes [2].
Further, the functionally distinct two-step mechanisms by which
Ad5 mediates cell attachment and entry facilitates targeting efforts.
The knob domain of the Ad5 fiber protein mediates viral
attachment via high-affinity binding to the human coxsackie-
and-adenovirus receptor (hCAR) [3]. Subsequent to the attach-
ment step, an Arg-Gly-Asp (RGD) motif in the penton base
capsomer associates with cellular av integrins, triggering viral
internalization and intracellular trafficking of the viral particle [4].
Thus, changes that redirect attachment to novel receptors are
unlikely to perturb Ad internalization activity.
Different strategies have been employed to limit the broad
tissue-specificity of Ad5 vectors, and redirect the viral tropism to
particular cell types. Early studies described the use of bi-specific
adapter proteins, composed of ligands fused to the ecto-domain of
hCAR, to block Ad5-hCAR interactions and simultaneously target
the virus to novel receptors [5–7]. These two-component systems
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ligands that can be attached to Ad, particularly bulky moieties,
such as single-chain antibodies (scFv), that often destabilize the
capsid when incorporated directly into the virus [8,9]. Further,
scFv require routing through the endoplasmic reticulum for proper
folding, but are redirected to the nucleus when fused to Ad capsid
proteins [8]. Nevertheless, two-component systems are incompat-
ible with oncolytic Ad or conditionally replicating Ad (CRAd)
vectors, as the adapters are lost after the first round of infection.
These systems are also difficult to optimize and require additional
regulatory approvals for clinical translation.
Despite the utility of two-component targeting systems, a
number of studies have continued to improve upon the conditions
permissive for stabilized and efficient genetic incorporation of
targeting ligands into the Ad capsid. Since specificity is provided at
the attachment phase, optimal targeting strategies utilize insertion
of ligand moieties within the fiber knob domain (reviewed in [1,2]).
Indeed, genetic insertion of targeting moieties into the HI-loop of
the fiber knob domain has provided a successful platform for Ad
retargeting strategies [10–12], but these insertions do not
completely abrogate Ad tropism to hCAR, unless the hCAR-
binding sites are also deleted [13,14].
Knob-deleted vectors offer two significant advantages over their
knob-insertion counterparts: First, knob has been shown to be
significantly immunogenic [15]. Second, it has recently been
demonstrated that soluble blood factors are responsible for Ad5
transduction of hepatocytes following intravascular injection. This
effect is primarily mediated by factor X (FX) interactions with the
Ad5 hexon protein [16,17]; however, earlier reports also suggest a
role for FIX/knob-mediated liver transduction in vivo [16,18].
Thus, strategies that eliminate immunogenic domains, while still
achieving significant targeting, offer improved clinical potential.
In this regard, our lab [19,20] and others [21,22] have
evaluated knob-deleted targeting platforms. A number of proof-
of-principle in vitro studies have highlighted the potential of this
strategy [9,19,20,23]. Recently, IL-13 incorporation into another
knob-deleted platform was demonstrated to allow efficient and
specific transduction of IL-13Ra2-expressing cells in vivo [24].
However, examples of knob-deleted platforms that target clinically
relevant cell types are limiting. Further, additional targeting
mechanisms will be required to route intravascularly-administered
virus to extracellular sites of pathology.
Since a number of diseases are characterized by large numbers
of inflammatory myeloid cell infiltrates [25], we sought to redirect
Ad tropism to myeloid lineage leukocytes. In doing so, we
hypothesize that systemically injected myeloid cell-targeted Ad
may transduce or traffic with the cells and localize therapeutic
gene expression to extravascular sites of pathology. Herein, we
describe the use of phage biopanning to identify a myeloid cell-
binding peptide (MBP) with the sequence WTLDRGY, and show
successful incorporation of MBP into our knob-deleted fiber
platform. The resulting virus, Ad.MBP, specifically binds and
transduces myeloid cell types ex vivo. These studies demonstrate the
feasibility of myeloid cell-targeting and are an important first-step
for endpoints aimed at targeted gene therapy for inflammatory
disease.
Results
Identification of a myeloid-binding peptide (MBP)
Phage display biopanning is a technique that has been
successfully used to identify ligands that bind to specific targets
in vitro as well as in vivo [26,27]. In order to identify novel myeloid
cell-targeting peptides we employed two complementary phage
biopanning strategies (Fig. 1A). First, a loop-constrained random
heptapeptide phage display library was panned over murine bone
marrow cells (BMCs) in vitro. Leukocytes were isolated by
fluorescence-activated cell sorting (FACS) and cell-bound phage
were eluted, amplified, and used as input for subsequent pans. A
single phage peptide, with the sequence WTLDRGY, was
identified after three rounds of in vitro panning (Table 1). For
the second approach, the phage library was infused into the tail
vein of one mouse. Shortly after injection, BMCs were extracted
and leukocytes were isolated by FACS. Leukocyte-bound phage
were eluted, amplified and used as input for subsequent pans in
additional mice. Three rounds of in vivo panning produced 15
individual phage peptides (from 32 clones sequenced) but failed to
generate a consensus sequence (Table 1). However, the
WTLDRGY phage peptide identified in vitro was also identified
in multiple rounds of in vivo panning.
As a first approach to evaluating cell binding specificities of the
peptides identified in our screen, murine BMCs were incubated
with clonal stocks of biotinylated phage and cell binding was
detected by flow cytometry. Compared to the other clones, the
phage with the WTLDRGY sequence demonstrated the highest
degree of binding to murine BMCs (Fig. 1B). In order to test the
cell-binding specificity as a function of the order of residues in the
WTLDRGY sequence, a control phage with the inverse sequence
(YGRDLTW) was synthesized and binding to murine BMCs was
evaluated by flow cytometry. Compared with the WTLDRGY
sequence, the inverted control sequence demonstrated substan-
tially reduced binding to murine BMCs (Fig. 1C).
We next sought to determine the specific residues within the
WTLDRGY sequence that conferred cell-binding. To evaluate
this, we developed a panel of seven scanning alanine mutant phage
(one for each of the residues of the WTLDRGY sequence) and
utilized our flow cytometry assay to assess phage binding to murine
BMCs. Scanning alanine mutagenesis of the WTLDRGY
sequence demonstrated that the sequence WTLXXGY is specif-
ically mediating leukocyte binding (Fig. 1D).
To better resolve the binding specificity of the WTLDRGY
clone to individual murine BMC populations, a 14 amino acid (aa)
version of the peptide (CWTLDRGYCSAEKA) was synthesized,
including a cysteine bridge, three C-terminal flanking residues
based on the phage pIII protein, and a biotinylated lysine residue
at position 13. The resulting peptide labeled a significant
percentage of total BMCs (data not shown). Greater than 87%
of these cells expressed the myeloid lineage marker, CD11b
(Fig. 2A), indicating the binding specificity is primarily restricted
to the myeloid (CD11b
+) lineage. Furthermore, the resulting
peptide labeled greater than 95% of total CD11b
+ BMCs
compared to controls (Fig. 2B,C), and this binding was not
specific to any particular CD11b
+ cell type (i.e. CD11b
+Ly6G
+ or
CD11b
+Ly6G
2 cells) (data not shown). Thereafter, we designated
the WTLDRGY sequence: myeloid cell-binding peptide (MBP).
Stable incorporation of MBP into Ad5
Ad5 cellular entry is mediated by distinct binding and
internalization events; the knob domain of Ad5 fiber initiates
attachment through interactions with CAR [3], while internaliza-
tion is mediated by distinct interactions between integrins and the
RGD motif within the Ad5 penton [4]. Our group has previously
developed a genetic Ad targeting platform, based on key fiber
modifications. Specifically, the knob domain was deleted to ablate
its broad tropism to CAR-expressing cells, and a 95 aa
trimerization domain of the T4 phage fibritin protein was inserted
to improve stability and allow display of novel targeting ligands
(Fig. 3A) [19,20]. The MBP sequence (WTLDRGY) as well as the
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were first inserted into a vector expressing this fiber-fibritin (FF)
platform (Fig. 3A) [9,20,28] to verify that genetic incorporation
produced stable fibers that maintained trimerization potential
(Fig. 3B). Following verification of viable fiber protein expression
and trimerization, we next assessed whether recombinant FF-MBP
retained myeloid cell-binding specificity (Fig. 3C). Notably, only
FF-MBP, but not FF-iMBP or Ad5 fibers, demonstrated binding to
murine CD11b
+ BMCs (Fig. 3C), indicating that myeloid cell-
binding specificity is entirely dependent on the presence of the
MBP sequence. In contrast, detection of Ad5 fiber binding to
CD11b
+ cells was only detected when the BMCs were isolated
from transgenic mice that express the native Ad5 receptor, hCAR
[29] (Fig. 3C).
Since fiber trimerization and myeloid cell-binding were
maintained, the FF-MBP and FF-iMBP (as a control) sequences
Figure 1. Identification of a myeloid cell-binding peptide (MBP) by phage display. (A) Schematic representation of the in vitro and in vivo
panning strategies used to identify putative myeloid-binding phage peptides from a cysteine-constrained random heptapeptide M13 phage display
library. A complete list of isolated phage peptides is presented in Table 1.( B) Flow cytometric detection of binding of individual biotinylated-phage
clones to bone marrow cells (BMCs) at 4uC. Background binding was assessed with insertless control phage. (C) Flow cytometric detection of binding
of WTLDRGY and YGRDLTW phage clones to BMCs at 4uC. Background binding was assessed with insertless control phage. (D) Phage binding to
CD11b
+ BMCs following scanning alanine mutagenesis of the WTLDRGY sequence. Each residue of the WTLDRGY sequence was substituted with an
alanine (A) and cloned into the original M13 phage display platform. Phage clones were then amplified and binding was assessed as in B and C. Gray
histograms indicate no phage control staining. Representative experiments are shown for B–D.
doi:10.1371/journal.pone.0037812.g001
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genomes by homologous recombination in E. coli and the resultant
genomes for Ad.MBP and Ad.iMBP were used for viral rescue in
E1-complementing cells. Traditionally, recombinant Ad5 is
propagated and purified from the hCAR-expressing HEK-293
cell line; however, recombinant knob-deleted vectors (such as
Ad.MBP and Ad.iMBP in the current study) are first rescued in a
wild type Ad5 fiber-complementing cell line, termed 293-F28 [30].
After several rounds of amplification in 293-F28 helper cells, the
resulting ‘mosaic’ virus (i.e. Ad5/MBP or Ad5/iMBP) was then
added to HEK-293 cells for final amplification of the homoge-
neous, non-mosaic virions. MBP- and iMBP-FF incorporation
were verified by Western blot on purified Ad particles (data not
shown), and transduction of the HEK-293 cell line was assessed
(Fig. 4) prior to subsequent functional characterization. As
expected, the knob-deleted Ad vectors (Ad.MBP and Ad.iMBP)
demonstrated significantly reduced (P,0.001) transduction of
CAR-expressing non-myeloid cells, compared to Ad5 (Fig. 4).
Functional characterization of Ad.MBP binding
We next assessed whether Ad.MBP maintained specificity for
the appropriate leukocyte subsets. To do so, Ad5, Ad.iMBP, and
Ad.MBP were added to total murine BMCs (2,000 VP per cell) at
4uC, and cell-bound virions were detected by flow cytometric
analysis. As with MBP fiber-binding, Ad.MBP virions demon-
strated a high degree of binding to CD11b
+ cells independent of
hCAR expression, and did not show any appreciable binding to
CD11b
2 cell types (Fig. 5A). Ad5 binding was not detected on
any BMC populations except those derived from transgenic mice
that express hCAR (Fig. 5A). The Ad.iMBP control virus did not
bind any BMC populations, including those from hCAR
+ mice
(Fig. 5A). Furthermore, Ad.MBP cell binding was dose dependent
and was only saturating at levels greater than 4,000 VP per cell
(Fig. 5B,C).
In addition to flow cytometric binding studies, we utilized
transmission electron microscopy (TEM) to visualize Ad.MBP
binding to BM neutrophils. The transmission electron micro-
graphs demonstrate numerous virion filled ruffles along the surface
of the neutrophil (Fig. 5D). In agreement with the flow cytometry
data, neither Ad5 nor Ad.iMBP was detected on these populations
by TEM (Fig. 5D). Taken together, these experiments (Fig. 5A,D)
demonstrate our ability to retarget virus binding to myeloid cell
populations. Furthermore, Ad.MBP, but not Ad5, bound to
CD11b
+ cells in the peripheral blood, spleen, and lung demon-
strating that Ad.MBP has the capacity to bind myeloid (CD11b
+)
cell populations from a variety of tissues ex vivo (Fig. 5E).
Functional characterization of Ad.MBP transduction
Finally, we assessed whether Ad.MBP binding to myeloid cells
would translate to enhanced infectivity of these populations,
compared to Ad5. To evaluate this, we first incubated total murine
BMCs with Ad5.Luc, Ad.iMBP.Luc, or Ad.MBP.Luc at 4uC, and
cultured the cells for 24 h before infectivity was assessed by
luciferase assay. At higher MOIs, Ad.MBP.Luc demonstrated
significantly higher transduction of total murine BMCs, compared
to both Ad5.Luc and Ad.iMBP.Luc (P,0.001) (Fig. 6A). To
determine if Ad.MBP transduction of BMCs was specific to the
myeloid lineage, we incubated murine BMCs with Ad5.GFP or
Ad.MBP.GFP as above, and the cells were cultured for 24 h
before infectivity of specific cell types was assessed by flow
cytometry. As expected, both Ad5 and Ad.MBP transduced less
than 5% of CD11b
2 cell types (data not shown). However,
compared to Ad5, Ad.MBP significantly enhanced transduction of
CD11b
+ cells up to four-fold (P,0.0001) (Fig. 6B) and resulted in
Table 1. Phage peptide candidate list.
Sequence Frequency
In vitro In vivo
Pan 3
a Pan 1 Pan 2 Pan 3.1
b Pan 3.2
c
WTLDRGY 5 1 2
PPNLKHS 2
PNHSSRT 1
PLVTAQN 1
VPKQTQM 1
LRGETVH 1
PNWPHWP 1 1 1
KFHLGAP 1 2 1
PPFGHTP 1
HPNFLPA 1
SPKTMKH 2 4
LLKDARL 4
SNAGRNA 2
LHNITST 1
TPSTAFQ 1
aOnly clones from the third round of in vitro panning were sequenced.
b10 minute post-infusion BM harvest.
c30 minute post-infusion BM harvest.
doi:10.1371/journal.pone.0037812.t001
Figure 2. Assessment of MBP synthetic peptide binding to
BMCs. (A–C) The heptapeptide sequence from the WTLDRGY phage
clone was incorporated into a 14 aa synthetic peptide (CWTLDRGYC-
SAEKA) termed MBP, with a cysteine bridge, three C-terminal flanking
residues derived from the phage pIII protein, and a biotinylated lysine
residue at position 13, for flow cytometric analysis of binding to murine
BMCs. (A) Percentage of total MBP-bound BMCs that are CD11b
+ or
CD11b
2 by flow cytometry. (B) Percentage of CD11b
+ (myeloid) and
CD11b
2 BMCs that are bound by MBP. (C) Representative histograms
for data in B. Gray histograms indicate control staining. Data in A and B
are means 6 s.e.m. of n = 3 experiments.
doi:10.1371/journal.pone.0037812.g002
Derivation of a Myeloid Cell-Binding Adenovirus
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37812significantly higher GFP
+ intensity of signal per cell (MFI) (data
not shown). The myeloid cell-specificity of MBP was further
demonstrated by pre-incubation of hCAR
+ BMCs with the 14 aa
MBP peptide, which significantly reduced Ad.MBP transduction
of CD11b
+ BMCs from mice, but not transduction with Ad5
(P,0.0001) (Fig. 6C). Furthermore, we assessed Ad.MBP
transduction of CD11b
+ cells under more physiological binding
conditions. To do so, total murine BMCs were incubated with
Ad5.GFP or Ad.MBP.GFP for 2 h at 37uC, after which unbound
virus was removed and the cells were cultured for an additional
22 h (24 h total). Under these conditions, both viruses transduced
CD11b
+ cells; however, Ad.MBP transduced a significantly higher
Figure 3. MBP fibers are viable and retain myeloid cell-binding specificity. (A) Diagram comparing wild type Ad5 and the MBP fibers. The
MBP fiber is derived from the 566FF platform that our group has previously developed [20]. Briefly, the knob domain is removed and replaced with
the trimerization region from the T4 phage fibritin protein fused to the MBP targeting ligand via a flexible linker ([GGGS]4). (B) Assessment of MBP
fiber viability by Western blot. 293T cells were harvested 48 h after transfection with expression plasmids for wild type Ad5, MBP, or inverted MBP
(iMBP) fibers. Protein supernatants from 293T cells were incubated at either 95uC (boiled, B) or room temperature (unboiled, U) prior to SDS-PAGE
separation. Unboiled samples demonstrate that the majority of fibers are trimerized. (C) Evaluation of fiber binding to CD11b
+ (myeloid) BMCs from
wild type (C57BL/6) and transgenic mice that express hCAR (hCAR Tg). 293T protein supernatants from B were added to BMCs and fiber-bound
CD11b
+ cells were detected by flow cytometry. A representative experiment is shown for C.
doi:10.1371/journal.pone.0037812.g003
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+ cells and resulted in a significantly higher
GFP MFI than Ad5 (P,0.001) (Fig. 6D,E). Together, these
experiments demonstrate that myeloid cell-binding (Fig. 5) via the
MBP sequence (WTLDRGY) significantly enhances Ad.MBP
transduction of target cells (Fig. 6).
Discussion
Recent breakthroughs have highlighted the potential of gene
therapy for a number of congenital and acquired illnesses. The
critical factor underlying improved therapeutic outcome is
typically the efficiency of gene delivery to diseased cells. Currently,
virus-based vectors are the most efficient means of gene transfer to
a number of cell types. Specifically, Ad5-based vectors represent
an efficient gene delivery platform and are currently being
evaluated for a number of clinical endpoints. However, as with
most viral-based vectors, Ad5 vectors are still limited by a lack of
specific and efficient gene targeting to clinically-relevant cell types.
Our group has previously described knob-deleted Ad fiber
platforms that ablate hCAR binding and facilitate stable display of
novel targeting elements [19,20]. Using these genetically-modified
vector platforms, we and others [21,22] have demonstrated the
ability to target novel cell types in a hCAR-independent manner
through incorporation of specific ligands, however, demonstration
of targeting clinically relevant receptors in vivo are limiting [24].
Selective binding is an important first-step in achieving specific
transduction; however, this strategy relies on physical access
between the virus and the target cells. Thus, for intravascular
delivery to extravascular targets, a mechanism must be in place to
deliver the virus to the sites of pathology. We sought to target Ad
to myeloid cell types, as these cells actively circulate, traffic to—
and participate in—many chronic inflammatory diseases. As a first
step in achieving this endpoint we utilized phage display
biopanning to identify peptides that bind to myeloid (CD11b
+)
cells. One particular phage sequence, WTLDRGY, identified in
sequential rounds of enrichment, was found to efficiently bind to
CD11b
+ but not CD11b
2 cells (namely, B and T cells) from a
number of tissues. Site-specific scanning alanine mutagenesis
demonstrated that the ordinate sequence WTLXXGY provides
the binding specificity. This myeloid cell-binding peptide (MBP)
sequence was then synthesized and used for further characteriza-
tion of the cell type binding specificity. We next sought to
determine whether the specificity of MBP was maintained when
incorporated into our fiber-fibritin platform. Despite its small size,
the specificity was maintained when expressed as recombinant
fibers, and finally when the recombinant fibers were genetically
incorporated into virions; demonstrating that this peptide can
efficiently redirect the binding of knob-deleted Ad virions.
Compared to Ad5 and non-specific peptide insertions, myeloid
cell-binding was only detected with Ad.MBP in multi-lineage total
bone marrow populations. The myeloid cell-binding specificity
directly translated to significantly improved transduction of the
myeloid cell types in total BM over Ad5, which was an increase of
up to four-fold over Ad5. This enhancement was significantly
inhibited by pre-incubation of target cells with the recombinant
WTLDRGY peptide. Furthermore, Ad.MBP transduction was
evaluated after allowing bone marrow leukocytes to first bind to
virus at 37uC instead of 4uC. Incubation of total BMCs with
Ad.MBP, resulted in significantly higher transduction of CD11b
+
leukocytes, compared to Ad5, however the difference was not as
striking as with binding done at 4uC. This result is not surprising,
as we would expect that incubation of Ad5 virions with highly
phagocytic CD11b
+ leukocytes (e.g. neutrophils) in a closed system
would result in increased non-specific uptake of the Ad5 particles.
Despite the increased transdcution with Ad5 under these
conditions, the unique ability of Ad.MBP to specifically bind to
CD11b
+ cells translated to a nine-fold increase in transgene
expression, compared to Ad5. Although we selected BM
leukocytes as our panning target population, we show that MBP
also binds myeloid leukocytes from an array of tissues (bone
marrow, peripheral blood, spleen, and lung), indicating specificity
is maintained for myeloid cells and has potential for use in a
number of inflammatory disorders.
Overall, these myeloid cell-targeting studies characterize the
specificity of Ad.MBP targeting ex vivo and are the first step in
demonstrating the potential of this virus for targeting clinically
relevant cell types in vivo. This vector may be suitable for ex vivo
gene transfer of myeloid cell types for reinfusion and subsequent
trafficking of therapeutics to inflammatory sites in vivo. Alterna-
tively, intravenous delivery may be possible if myeloid cell-binding
in vivo occurs with high efficiency. In either case, we hypothesize
the gene-modified leukocytes will traffic intravascularly, extrava-
sate towards inflammatory signals, and this inside-out delivery
approach may enhance therapeutic delivery to chronic sites of
inflammation. Current studies are underway to identify the
cognate receptor of MBP, and to determine whether systemic
targeting of myeloid cell types with Ad.MBP will allow virus/
therapeutic egress and trafficking to extravascular sites of
inflammation.
Materials and Methods
Ethics statement for animal use
C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME)
between the ages of 6 to 10 weeks old were used in this study.
Transgenic hCAR (hCAR Tg) mice were a gift from Dr. Sven
Pettersson (Karolinska Institute, Stockholm, Sweden). These mice
Figure 4. Knob-deleted Ad virus (Ad.MBP and Ad.iMBP)
transduction of the CAR-expressing cell line, 293. Ad5.Luc,
Ad.iMBP.Luc, and Ad.MBP.Luc were added to QBI-293A cells in 24-well
plates at increasing multiplicities of infection (MOI) for 24 h at 37uC
before luciferase activity was assessed at 24 h post-infection. Data are
means 6 s.d. of a representative experiment with triplicate samples.
##, P,0.01; **, P,0.01 compared to both Ad5 and Ad.iMBP;
***, P,0.001 compared to both Ad5 and Ad.iMBP.
doi:10.1371/journal.pone.0037812.g004
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the human ubiquitin-C promoter, allowing hCAR expression in a
variety of tissues [29]. All methods were approved by the
Institutional Animal Care and Use Committee (IACUC) at the
University of Alabama at Birmingham (Animal Protocol Number
[APN] 7618 and 9313) and performed according to their and the
National Institutes of Health guidelines.
Figure 5. Genetic incorporation of MBP fiber into Ad5 (Ad.MBP) retains myeloid cell-binding specificity. (A) Assessment Ad5-, Ad.iMBP-
, and Ad.MBP-binding (2,000 VP per cell) at 4uC to myeloid (CD11b
+) and non-myeloid (CD11b
2) BMCs from C57BL/6 and transgenic mice that express
hCAR (hCAR Tg) by flow cytometry. (B,C) Evaluation of Ad.MBP-binding to CD11b
+ BMCs at increasing MOI at 4uC. (B) Percentage of total CD11b
+
BMCs bound by Ad.MBP. (C) Mean fluorescent intensity (MFI) of Ad.MBP-binding to CD11b
+ BMCs. (D) Evaluation of Ad5-, Ad.iMBP-, and Ad.MBP-
binding (500 VP per cell) at 4uC to murine BM neutrophils was also determined by transmission electron microscopy (TEM). Arrows indicate Ad.MBP
virions along the cell surface. Scale bar, 500 nm. (E) Assessment of Ad5- or Ad.MBP-binding (2,000 VP per cell) at 4uC to CD11b
+ cells from BM,
peripheral blood (PB), spleen, and lung by flow cytometry. Binding to CD11b
2 BMCs is also shown for comparison. Representative experiments are
shown for A, D, and E. Data in B and C are means 6 s.d. of a representative experiment with triplicate samples.
doi:10.1371/journal.pone.0037812.g005
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HEK-293 and 293T (Microbix, Toronto, Canada), QBI-293A
(Qbiogene, Montreal, Canada), and 293-F28 cell lines were all
propagated in Dulbecco’s modified Eagle’s medium (DMEM)-F12
medium supplemented with 10% (vol/vol) fetal calf serum (FCS),
L-glutamine (2 mM), penicillin (100 I.U./mL) and streptomycin
(100 mg/mL). The 293-F28 cell line, a derivative of HEK-293,
expresses the Ad5 wild type fiber for mosaic virus propagation as
described previously [30]. All cells were propagated at 37uCi na
humidified atmosphere of 5% CO2.
Phage display
For in vivo panning, 2610
11 plaque-forming units (pfu) of the
Ph.D.-C7C cysteine-constrained heptapeptide M13 Phage Display
Library (New England Biolabs, Ipswich, MA) was diluted in
200 mL a-MEM and infused into the tail vein (t.v.) of one mouse.
After 10 min, BMCs were flushed from femoral and tibial marrow
cavities with a-MEM supplemented with 2% FCS (a-MEM/2%).
Cells were filtered through 40 mm nylon strainers and centrifuged
at 250 g. Pellets were resuspended in erythrocyte lysis buffer
(155 mM ammonium chloride, 20 mM sodium bicarbonate and
1 mM EDTA, pH 8), centrifuged at 250 g, and finally resus-
pended in phosphate buffered saline (PBS) supplemented with 2%
FCS (FACS buffer). Cells of interest were isolated by fluorescence-
activated cell sorting (FACS). Cell-bound phage were eluted with
0.2 M Glycine-HCl (pH 2.2), neutralized with 1 M Tris-HCl
(pH 9.1), then amplified and sequenced according to NEB’s
instructions. This process was repeated two times with the
amplified output phage after each round used as input for the
subsequent panning experiment. For the third round of panning,
two animals were each infused with 2610
11 pfu of the output
phage from the second round of panning. One mouse was
sacrificed after 10 min and the other mouse was sacrificed after
30 min. For in vitro panning, 2610
11 pfu of the same starting
library from the manufacturer was added to 2.5610
7 BMCs
isolated from naı ¨ve mice (as above) and incubated at 4uC for 6 h.
Excess phage were removed by centrifuging the cells at 250 g and
cells of interest were then isolated by FACS. Cell-bound phage
were eluted, amplified and sequenced as described above for a
total of three rounds of panning.
Phage vector construction
M13-MBP phage mutants were synthesized by substituting an
alanine for each of the seven residues of the MBP sequence
(WTLDRGY). An inverse MBP (iMBP) control mutant with the
Figure 6. Myeloid cell-binding specificity of Ad.MBP enables
enhanced transduction of CD11b
+ BMCs in vitro. (A) Transduction
of total BMCs by Ad5.Luc, Ad.iMBP.Luc, or Ad.MBP.Luc at increasing MOI
as measured by luciferase activity (relative expression units) and
normalized to protein concentration of individual samples. Total BMCs
were mixed with virus at 4uC for 60 min, then washed, and plated at
37uC for 24 h prior to luciferase assay. ***, P,0.001 compared to Ad5;
##, P,0.01 compared to AdiMBP; ###, P,0.001 compared to
AdiMBP. (B) Flow cytometric analysis of CD11b
+ BMCs transduced with
Ad5.GFP or Ad.MBP.GFP at increasing MOI. Total BMCs were mixed with
virus at 4uC for 20 min, then washed, and plated at 37uC for 24 h.
CD11b
2 BMCs were not efficiently transduced by either virus (data not
shown). ***, P,0.0001. (C) Flow cytometric analysis of CD11b
+ BMCs
pre-incubated with the 14 aa MBP peptide and then transduced with
Ad5.GFP or Ad.MBP.GFP. Total BMCs from transgenic mice that express
hCAR were mixed with the MBP peptide (25 mg) prior to virus (MOI =
500) as in B, or mixed with virus alone (MOI = 500), then washed, and
plated at 37uC for 24 h. ***, P,0.0001. (D,E) Total BMCs were mixed
with Ad5.GFP or Ad.MBP.GFP (MOI = 500) at 37uC for 2 h, then washed,
and plated at 37uC for a total of 24 h, before flow cytometric analysis
was performed. (D) Percentage of total CD11b
+ BMCs transduced by
either virus. CD11b
2 BMCs were not efficiently transduced by either
virus (data not shown). (E) Mean fluorescent intensity (MFI) of GFP for
CD11b
+ BMCs. ***, P,0.001. Data in A–E are means 6 s.d. of
representative experiments with triplicate samples.
doi:10.1371/journal.pone.0037812.g006
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different 56 basepair (bp) Acc65I-EagI oligo linkers comprising the
MBP, iMBP, or mutant MBP sequence were cloned into the
Acc65I-EagI-linearized M13KE cloning vector (New England
Biolabs) for transformation of E. coli ER2738 without negative
selection according to the New England Biolabs protocol. Phage
DNA was isolated according to the New England Biolabs protocol
and positive clones were identified by PCR and verified by
sequencing.
Phage preparation
Large scale stocks of M13 phage clones were prepared
essentially according to the New England Biolabs protocol. Briefly,
amplified phage were recovered by PEG precipitation of
supernatants from 25 mL cultures and resuspended in 1 mL
Tris-buffered saline (TBS) with 50% glycerol. Titers were
determined by dilution plaque assays on E. coli ER2738. In order
to detect phage binding to BMCs, the original (15 clones identified
from phage panning) M13 phage preps were biotinylated with EZ-
LinkH Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL) according to
the manufacturer’s protocol, while the M13-MBP mutant phage
preps used in subsequent binding experiments were not biotiny-
lated.
Ad vector construction
The shuttle vectors, pKan-566FF-MBP and pKan-566FF-iMBP
(used for Ad5 fiber replacement), were generated by cloning a
54 bp BamHI-BclI oligo linker comprising the MBP (or iMBP)
sequence into the BamHI-linearized vector pKan-566FF-BaeI
[9,20]. The mammalian expression vectors, pVS-566FF-MBP
and pVS-566FF-iMBP, containing the modified fiber genes, were
then created by replacing the 1.5 kilobase (kb) AgeI fragment from
the expression vector pVS-566FF-DCd with similar sized AgeI
fragments from the above shuttle vectors. Plasmid pVS-566FF-
DCd was constructed by deleting a 0.2 kb BamHI-SwaI fragment,
containing the Cd domain, from pVS-566FF-Cd [9,20] and
replacing it with a 58 bp oligo linker containing an AgeI site. The
expression vector pVSII containing the wild type Ad5 fiber gene is
described elsewhere [28].
Recombinant non-replicating Ad genomes containing the
modified MBP fiber genes (pAd.MBP.Luc, pAd.iMBP.Luc, and
pAd.MBP.GFP) were then derived by homologous DNA recom-
bination in E. coli BJ5183 between the EcoRI-digested shuttle
vectors and SwaI-linearized, pVK700 and pVK900, as previously
described [31]. The plasmids pVK700 and pVK900 are
derivatives of pTG3602 [31] which contains full E1 and fiber
gene deletions [32,33]. In place of the E1 region, pVK700 and
pVK900 express the firefly luciferase (Luc) and eGFP reporter
genes, respectively, from the CMV immediate early (IE) promoter.
Genome size was characterized by restriction digest and gel
electrophoresis and sections of the genomes were sequenced to
verify both the fiber and transgene regions.
Viruses
Ad.MBP and Ad.iMBP viruses were first generated by
transfection of 293-F28 cells with PacI-digested pAd.MBP and
pAd.iMBP genomes using Lipofectamine-2000 (Invitrogen, Carls-
bad, CA) as described previously [30]. Rescued virions at this
point are referred to as ‘‘mosaic’’ because they contain both the
wild type Ad5 fibers and 566FF-MBP (or -iMBP) fibers. To
generate virions with only 566FF-MBP or -iMBP fibers, we
transduced QBI-293A cells with mosaic Ad5/MBP and Ad5/
iMBP viruses following further rounds of amplification in 293-F28
cells. Cells were harvested after CPE was observed and virus was
purified by two rounds of CsCl density ultracentrifugation and
dialyzed in storage buffer (10% glycerol, 1 mM MgCl2, and
10 mM HEPES, pH 7.8). Isogenic control E1-deleted Ad5.Luc
and Ad5.GFP vectors [19] (each expressing transgene from the
CMV-IE promoter) were generated by infection of QBI-293A cells
with purified virions. Cells were harvested after CPE was observed
and virus was purified as above. Virus particle (VP) concentration
was determined at 260 nm by using a conversion factor of
1.1610
12 VP per mL per absorbance unit as previously described
[34].
Recombinant fiber expression system
293T cells were seeded on 10-cm dishes prior to transfection
with the expression plasmids pVS-566FF-MBP, pVS-566FF-
iMBP, and pVSII (8.5 mg DNA per dish) using Lipofectamine-
2000 (Invitrogen) according to the manufacturer’s protocol. Cells
(including mock transfected control) were harvested after 48 h,
washed and then frozen in PBS (1 mL per 10-cm dish of cells).
Protein supernatants (clarified of cell debris) were collected after
three freeze/thaw cycles and protein concentrations were deter-
mined by DC Protein Assay (Bio-Rad, Hercules, CA).
Western blotting
293T protein supernatants (10 mg total protein) or purified Ad5,
Ad.iMBP, and Ad.MBP virions (1610
9 VP) were diluted in
Laemmli sample buffer and incubated at either 95uC (boiled) or
room temperature (unboiled) for 10 min and then separated by
SDS-PAGE (10–12% resolving gels). Proteins were subsequently
electroblotted onto PVDF membranes for western blot using the
mouse 4D2 monoclonal antibody (mAb) to the Ad5 fiber tail
domain (Lab Vision, Fremont, CA) followed by horseradish
peroxidase-conjugated rabbit polyclonal secondary antibody to
mouse IgG (Dako, Carpinteria, CA) as previously described [33].
Blots were developed using the Amersham ECL Plus Western
Blotting Detection Kit (GE Healthcare, Piscataway, NJ). Precision
Plus Protein Kaleidoscope Standards (Bio-Rad) were used to
estimate molecular weights of bands.
In vitro binding experiments
Prior to binding studies, BMCs (isolated as above), peripheral
blood (isolated by cardiac puncture into heparinized tubes), and
spleen cells (filtered through 40 mm strainers) were all centrifuged
at 250 g. Lungs were removed, chopped into small pieces,
resuspended in 1 mL Hank’s Balanced Salt Solution (HBSS)
supplemented with 0.14 Wu ¨nsch units Liberase (Roche, India-
napolis, IN) and 100 Units DNase I (Roche) and incubated for
25 min at 37uC while shaking [35]. Lung homogenates were then
passed through 40 mm strainers and centriguged at 250 g. Cell
pellets from all sources were resuspended in erythrocyte lysis
buffer, centrifuged at 250 g, then washed and resuspended in
FACS buffer, for subsequent experimentation. All binding
experiments were carried out on ice or at 4uC. For all binding
experiments, antibodies to various cell surface markers were
included with secondary antibody staining to help distinguish
various cell populations by flow cytometry as described below.
For phage and peptide binding, 5610
8 pfu biotinylated phage
or 10 mg of biotinylated peptide were added to 1610
6 BMCs. The
biotinylated peptide was synthesized at the Cleveland Clinic
Lerner Research Institute Molecular Biotechnology Core (Cleve-
land, OH) and dissolved in PBS at 5 mg/mL. Cell-bound
biotinylated phage or peptide was detected with APC-conjugated
streptavidin (BD Pharmingen, San Diego, CA) by flow cytometry.
Unbiotinylated phage-binding was detected with mouse monoclo-
nal antibody to the M13 major coat protein pVIII (GE
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antibody to mouse IgG (SouthernBiotech, Birmingham, AL).
For fiber protein binding experiments, 575 mg( ,100 mL) of
293T protein supernatant was used to stain 1610
6 BMCs and cell-
bound fiber was detected with mouse 4D2 mAb to the Ad5 fiber
tail domain (Lab Vision, Fremont, CA) followed by Alexa Fluor
488 (A488)-conjugated goat polyclonal secondary antibody to
mouse IgG (Invitrogen Molecular Probes, Eugene, OR).
For characterization of Ad-binding of BMCs, peripheral blood,
spleen and lung, Ad.MBP, Ad.iMBP, or Ad5 were incubated with
1610
6 cells at different multiplicity of infection (MOI). Cellular-
bound Ad was detected with rabbit polyclonal antiserum to Ad5
(as previously described [36]) followed by either A488-conjugated
goat polyclonal or A647-conjugated chicken polyclonal secondary
antibody to rabbit IgG (Invitrogen Molecular Probes).
Transmission electron microscopy (TEM)
BMCs were isolated as above and then neutrophils were
purified by negative magnetic bead-based antibody selection to
remove T and B cells, erythrocytes, and monocytes/macrophages
as described previously [37]. Ad5, Ad.iMBP, and Ad.MBP binding
was carried out, as described above (MOI = 500). Virus-bound
cells were fixed in a modified Karnovsky’s fixative (2%
Paraformaldehye and 2% Glutaraldehyde in 0.1 M phosphate
buffer). After fixation the specimens were rinsed several times with
PBS followed by post-fixation with 1% osmium tetroxide in
phosphate buffer for 1 h. After rinsing, the tissue specimens were
dehydrated through a series of graded ethyl alcohols from 70 to
100%. After dehydration, the samples were embedded in EMbed
812 resin (Electron Microscopy Sciences, Hatfield, PA). Images
were collected using a FEI Tecnai F20 FEG transmission electron
microscope (FEI, Hillsboro, OR) at 80 KV in the UAB High
Resolution Imaging Facility.
In vitro transduction
For QBI-293A infection, Ad5.Luc, Ad.iMBP.Luc, or Ad.-
MBP.Luc at different MOI were incubated with 0.2610
6 QBI-
293A cells in DMEM-F12 media as described above, and then
luciferase activity was assayed at 24 h using the luciferase assay
system (Promega, Madison, WI) and a TD-20/20 luminometer
(Turner Designs, Sunnyvale, CA). Protein concentrations of cell
culture samples were determined by DC Protein Assay (Bio-Rad)
in order to normalize relative light units (RLU) values from
different samples.
For BMC infection, BMCs were harvested and erythrocytes
lysed as above. Ad5.Luc, Ad.iMBP.Luc, or Ad.MBP.Luc were
incubated with 1610
6 BMCs at different MOI in a-MEM/2% for
60 min at 4uC. Ad.MBP.GFP or Ad5.GFP were incubated with
1610
6 BMCs at different MOI in a-MEM/2% for 20 min at 4uC
or 2 h at 37uC. For both experiments, cells were washed twice to
remove unbound virus and then plated in 1 mL of a-MEM
supplemented with 20% FCS, SCF (50 ng/mL), IL-3 (20 ng/mL),
and IL-6 (50 ng/mL) (cytokines from R&D Systems, Minneapolis,
MN). For blocking experiments, 1610
6 BMCs from hCAR Tg
mice were pre-incubated with 25 mg MBP peptide for 20 min at
4uC before addition of virus (MOI = 500). After incubation for
24 h at 37uC, cells from all BMC experiments were harvested, and
assayed for luciferase activity (as for QBI-293A experiment above)
or stained for flow cytometry (and detection of GFP expression).
Flow cytometry
Antibodies to CD11b (clone M1/70), Gr-1 (RB6-8C5), and Ly-
6G (1A8), were all purchased from BD Pharmingen. Other
antibodies were already mentioned. Antibody to CD16/32
(2.4G2; BD Pharmingen) was used to block endogenous mouse
Fc Receptors before antibody staining. For binding studies, 2.4G2
was added after cells had been incubated with phage, peptide,
293T cell lysate, or virus but before staining with other antibodies.
Data were acquired on a FACSCalibur or LSRII (BD Biosciences,
Franklin Lakes, NJ) and analyzed with FlowJo v.7.6.1 (Tree Star,
Inc., Ashland, OR).
Statistical analysis
Data are presented as means 6 s.d. or s.e.m. where appropriate.
Statistical differences between groups were determined by analysis
of variance (with Bonferroni post-test correction for comparisons
of three or more groups) using Prism 4.0 (GraphPad Software, La
Jolla, CA). Statistical significance was accepted at P,0.05.
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